Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder.

Jason D RobinsonYong CuiMaher Karam-HageGeorge KypriotakisFrancesco VersaceNassima Ait-Daoud TiouririneRobert M AnthenelliPaul M Cinciripini

Published in: Alcoholism, clinical and experimental research (2022)

These findings suggest that high-dose topiramate (up to 250 mg/day) decreases the motivational salience of both drug-related and emotional cues among smokers with AUD. However, the nonsignificant mediation analyses preclude any firm conclusions about whether this effect represents one of topiramate's therapeutic mechanisms of action.

Keyphrases

alcohol use disorder
high dose
smoking cessation
functional connectivity
low dose
stem cell transplantation
social support
adverse drug